WHAT WE’RE READING- JOURNAL CLUB November 5, 2024 OCTOBER 2024 Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery DiseaseThrombectomy for Stroke With Large Infarct on Noncontrast CT The TESLA Randomized Clinical TrailLeft Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite AnticoagulationOptimal Timing of Anticoagulation After Acute Ischemic Stroke With Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomized Controlled Trial
WHAT WE’RE READING- JOURNAL CLUB October 2, 2024 SEPTEMBER 2024 Gene-Gene Interaction Between Factor-XI and ABO Genes in Cerebral Venous ThrombosisInflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in WomenBalloon Angioplasty vs Medical Management for Intracranial Artery Stenosis the BASIS Randomized Clinical Trail
WHAT WE’RE READING- JOURNAL CLUB September 5, 2024 AUGUST 2024 Lowering Systolic Blood Pressure to Less Than 120MM HG Versus Less Than 140 MM HG in Patients with High Cardiovascular Risk with And Without Diabetes or Previous Stroke: An Open-label, Blinded-Outcome, Randomised Trail
WHAT WE’RE READING- JOURNAL CLUB June 26, 2024June 26, 2024 JUNE 2024 Intensive Ambulance Delivered Blood Pressure Reduction in Hyperacute StrokeDecompressive Craniectomy Plus Best Medical Treatment Verus Best Medical Treatment Alone for Spontaneous Severe Deep Supratentorial Intracerebral Hemorrhage: A Randomized Controlled Clinical TrailTenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ThrombectomyLong-term Colchicine for the Prevention of Vascular Recurrent Events in Non-Cardioembolic Stroke (CONVINCE): A Randomized Controlled Trail
WHAT WE’RE READING- JOURNAL CLUB May 29, 2024 May 2024 Tranexamic Acid Verus Placebo in Individuals with Intracerebral Hemorrhage Treated within 2 H of Symptom Onset (STOP-MSU): An International, Double-Blind, Randomized, Phase 2 TrailTenecteplase Verses Standard of Care for Minor Ischemic Stroke with Proven Occlusion (TEMPO-2): A Randomized Open Label, Phase 3 Superiority Trail
WHAT WE’RE READING- JOURNAL CLUB May 2, 2024 April 2024 Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke the ATAMIS Randomized Clinical TrailIncidence and Outcomes of Posterior Circulation Involvement in Moyamoya DiseaseTrail of Early Minimally Invasive Removal of Intracerebral Hemorrhage
WHAT WE’RE READING- JOURNAL CLUB March 26, 2024 March 2024 Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke The TASTE-SL Randomized Clinical TrailFunctional Outcomes in Conservatively vs Surgically Treated Cerebellar InfarctsMicroplastics and Nanoplastics in Atheromas and Cardiovascular Events
WHAT WE’RE READING- JOURNAL CLUB February 27, 2024 FEBRUARY 2024 Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
WHAT WE’RE READING- JOURNAL CLUB February 15, 2024 January 2024 Apixaban versus Aspirin for Embolic Stroke of Undetermined SourceArgatroban in Patients with Acute Ischemic Stroke with Early Neurological Deterioration A Randomized Clinical TrailDual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
WHAT WE’RE READING- JOURNAL CLUB February 15, 2024 December 2023 Alberta Stroke Program Early Computed Tomography Score, Infarct Core Volume, and Endovascular Therapy Outcomes in Patients with Large InfarctSafety and Efficacy of Prophylactic Levetiracetam for Prevention of Epileptic Seizures in the Acute Phase of Intracerebral Haemorrhage (PEACH): a Randomized, Double-Blind, Placebo-Controlled, Phase 3 TrailTime Window for Induced Hypertension in Acute Small Vessel Occlusive Stroke With Early Neurological Deterioration
Penn Neurology - Division of Stroke and Vascular Neurology 